top of page

NCI-2022-08263

Updated: Feb 21

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer


This research study investigates whether combining SBRT for the primary lung tumor with concurrent mediastinal chemoradiation improves outcomes for patients with locally-advanced NSCLC compared to standard treatments. This refers to lung cancers that are more advanced than early-stage (stage I or II) but have not spread extensively to distant parts of the body (stage III). SBRT is a technique where very precise, high-dose radiation is delivered to the tumor, typically in a few (often 1-5) sessions. It's used for localized tumors and aims to deliver radiation with minimal damage to surrounding healthy tissue.


For more information about the trial, click the link below:

Clinical Trial Site: Einstein


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2024-07005

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial...

 
 
 
NCI-2024-02382

A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) This is a platform...

 
 
 
NCI-2024-06081

A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH...

 
 
 

Comments


bottom of page